NIOSH logo and tagline

Salicylic acid, acetate

RTECS #
VO0700000
CAS #
50-78-2; 2349-94-2; 11126-35-5; 11126-37-7; 26914-13-6; 98201-60-6
See: NMAM or OSHA Methods
Updated
March 2019
Molecular Weight
180.17
Molecular Formula
C9H8O4
Synonyms
2-(Acetyloxy)benzoic acid
2-Acetoxybenzoic acid
A.S.A.
A.S.A. empirin
AC 5230
Acenterine
Acesal
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetylin
Acetylsal
Acetylsalicylic acid
Acetylsalicylic acid (ACGIH)
Acetylsalicylsaure (German)
Acide acetylsalicylique (French)
Acido acetilsalicilico (Italian)
Acido O-acetil-benzoico (Italian)
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
ASA
Asagran
Aspergum
Aspirdrops
Aspirin
Aspirina 03
Aspro Clear
Asteric
Benaspir
Benzoic acid, 2-(acetyloxy)- (9CI)
Bialpirinia
Caprin
Colfarit
Contrheuma retard
Delgesic
Dolean pH 8
Duramax
ECM
Ecotrin
Empirin
Endydol
Entericin
Enterosarine
Entrophen
Globoid
Helicon
Idragin
Istopirin
Kapsazal
Kyselina 2-acetoxybenzoova (Czech)
Kyselina acetylsalicylova (Czech)
Measurin
Medisyl
Micristin
Neuronika
Novid
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
Polopiryna
Rheumin tabletten
Rhonal
Salacetin
Salcetogen
Saletin
Solpyron
Triple-sal
Xaxa
Yasta
Zorprin

Skin and Eye Irritation and References

Route/OrganismDoseEffectReference
skin /human 10%CODEDG 60,325,2009

Mutation Data and Reference

System TestRoute/Organism/TissueDoseReference
Cytogenetic Analysisfibroblast/human100 mg/LACYTAN 16,41,1972
Cytogenetic Analysisleukocyte/human100 µg/LSCIEAS 171,829,1971
Cytogenetic Analysislymphocyte/human10 mg/LBEXBAN 78,1194,1974
Cytogenetic Analysislung/hamster1660 mg/LGMCRDC 27,95,1981
DNA inhibitionlymphocyte/human100 µmol/LFEPRA7 36,1748,1977
DNA repair/Bacillus subtilis5 mg/discJNUDAT 34,183,1992
micronucleus testlung/hamster626 µmol/L/48H (-enzymatic activation step)MUTAEX 26,709,2011
morphological transformembryo/rat108 µg/plateJJATDK 1,190,1981
other mutation test systemslymphocyte/human75 mg/LNEZAAQ 37,673,1982
sister chromatid exchangeintraperitoneal/mouse100 mg/kgMUREAV 370,1,1996

Reproductive Effects Data and References

Route/OrganismDoseEffectReference
intrauterine/rat 2 mg/kg (4D pregnant)Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea)CCPTAY 24,283,1981
oral/mouse 1200 mg/kg (8-9D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)
LANCAO 1,606,1965
oral/mouse 800 mg/kg (17D pregnant)Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Other effects to embryo or fetus

Reproductive: Other developmental abnormalities
APTOA6 29,250,1971
oral/mouse 19200 mg/kg (6-21D pregnant)Reproductive: Effects on newborn: Stillbirth

Reproductive: Effects on newborn: Other neonatal measures or effects
LANCAO 1,565,1964
oral/mouse 2500 mg/kg (6-15D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
TXCYAC 37,315,1985
oral/cat 300 mg/kg (10-15D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
TJADAB 14,21,1976
oral/rabbit 800 mg/kg (8-15D pregnant)Reproductive: Specific developmental abnormalities: Body wall

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
BANMAC 159,433,1975
oral/rabbit 1800 mg/kg (8-16D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Effects on embryo or fetus: Fetal death
TXAPA9 10,244,1967
oral/rabbit 1750 mg/kg (6-12D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)LANCAO 1,763,1964
oral/rabbit 600 mg/kg (2D prior to copulation)Reproductive: Effects on fertility: Other measures of fertilityJJPAAZ 28,909,1978
oral/Dog 3200 mg/kg (23-30D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Specific developmental abnormalities: Respiratory system
TJADAB 20,313,1979
oral/woman 7500 mg/kg (34-37W pregnant)Reproductive: Other effects on female

Reproductive: Effects on newborn: Stillbirth
AJPEEK 15,39,1998
oral/woman 700 mg/kg (35-36W pregnant)Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Effects on newborn: Biochemical and metabolic
CPEDAM 34,174,1995
oral/woman 546 mg/kg (37-39W pregnant)Reproductive: Effects on newborn: Other postnatal measures or effectsCPEDAM 32,740,1993
oral/woman 546 mg/kg (37-39W pregnant)Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Other developmental abnormalities
CPEDAM 32,740,1993
oral/woman 17550 mg/kg (12-39W pregnant)Reproductive: Maternal effects: ParturitionLANCAO 2,1159,1973
oral/woman 100 mg/kg (37W pregnant)Reproductive: Effects on newborn: Other neonatal measures or effectsNEJMAG 307,909,1982
oral/woman 17280 mg/kg (1-39W pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Specific developmental abnormalities: Respiratory system

Reproductive: Effects on newborn: Apgar score (human only)
JOPDAB 92,478,1978
oral/woman 189 mg/kg (12-39W pregnant)Reproductive: Maternal effects: Parturition

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Blood and lymphatic systems (including spleen and marrow)
NEJMAG 321,357,1989
oral/rat 1 gm/kg (12D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetal death
TJADAB 27,261,1983
oral/rat 2100 mg/kg (14D male)Reproductive: Paternal effects: Testes, epididymis, sperm ductIJEBA6 18,1408,1980
oral/rat 200 mg/kg (9D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)TJADAB 16,127,1977
oral/rat 10 mg/kg (22D pregnant)Reproductive: Maternal effects: Parturition

Reproductive: Effects on newborn: Stillbirth

Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth)
NATUAS 240,21,1972
oral/rat 500 mg/kg (9D pregnant)Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Eye, ear

Reproductive: Specific developmental abnormalities: Musculoskeletal system
ANREAK 163,175,1969
oral/rat 125 mg/kg (12D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal systemTJADAB 27,261,1983
oral/rat 1 gm/kg (3D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)YHHPAL 31,416,1996
oral/mouse 3825 mg/kg (1D preg-30D after birth)Reproductive: Effects on newborn: Other postnatal measures or effectsBJCAAI 88,1480,2003
oral/rat 250 mg/kg (9D pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Specific developmental abnormalities: Respiratory system

Reproductive: Other developmental abnormalities
TOXID9 60,220,2001
oral/rat 500 mg/kg (10D pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Specific developmental abnormalities: Respiratory system

Reproductive: Other developmental abnormalities
TOXID9 60,220,2001
oral/rat 500 mg/kg (11D pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) systemTOXID9 60,220,2001
oral/rat 3000 mg/kg (6-17D pregnant)Reproductive: Specific developmental abnormalities: Respiratory system

Reproductive: Other developmental abnormalities
TOXID9 60,220,2001
oral/rat 720 mg/kg (18-21D pregnant)Reproductive: Effects on newborn: Other postnatal measures or effectsTXCYAC 232,257,2007
oral/rabbit 4550 mg/kg (7-19D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)BDERB* 68,38,2003
oral/rat 250 mg/kg (9D pregnant)Reproductive: Effects on embryo or fetus: Fetal deathBDERB* 68,27,2003
oral/rat 500 mg/kg (9D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
BDERB* 68,27,2003
oral/rat 500 mg/kg (9D pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Other developmental abnormalities
BDERB* 68,27,2003
oral/rat 625 mg/kg (9D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal systemBDERB* 68,27,2003
oral/rat 625 mg/kg (10D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)
BDERB* 68,27,2003
oral/rat 625 mg/kg (10D pregnant)Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) systemBDERB* 68,27,2003
oral/rat 500 mg/kg (10D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)BDERB* 68,27,2003
oral/rat 750 mg/kg (10D pregnant)Reproductive: Other developmental abnormalitiesBDERB* 68,27,2003
oral/rat 500 mg/kg (11D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)BDERB* 68,27,2003
oral/rat 750 mg/kg (11D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Specific developmental abnormalities: Musculoskeletal system
BDERB* 68,27,2003
oral/rat 750 mg/kg (11D pregnant)Reproductive: Specific developmental abnormalities: Urogenital systemBDERB* 68,27,2003
oral/rat 600 mg/kg (6-17D pregnant)Reproductive: Effects on embryo or fetus: Fetal deathBDERB* 68,27,2003
oral/rat 3000 mg/kg (6-17D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)
BDERB* 68,27,2003
oral/rat 3000 mg/kg (6-17D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system
BDERB* 68,27,2003
oral/rat 3000 mg/kg (6-17D pregnant)Reproductive: Specific developmental abnormalities: Gastrointestinal system

Reproductive: Specific developmental abnormalities: Urogenital system

Reproductive: Other developmental abnormalities
BDERB* 68,27,2003
oral/rat 2700 mg/kg (7-16D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Other developmental abnormalities
TOLED5 196S,S183,2010
oral/rat 2800 mg/kg (7-16D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Other effects to embryo or fetus
TOLED5 196S,S183,2010
oral/rat 250 mg/kg (10D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
RTOPDW 54,308,2009
oral/rat 500 mg/kg (10D pregnant)Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)RTOPDW 54,308,2009
subcutaneous/rat 1800 mg/kg (12D male)Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count)

Reproductive: Paternal effects: Testes, epididymis, sperm duct
INJFA3 23,282,1978
subcutaneous/rat 380 mg/kg (9D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Other developmental abnormalities
BCPCA6 22,407,1973
subcutaneous/rat 500 mg/kg (11D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetal death

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)
RCOCB8 38,209,1982
subcutaneous/rat 500 mg/kg (11D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal systemRCOCB8 38,209,1982
subcutaneous/rat 500 mg/kg (11D pregnant)Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)
RCOCB8 39,179,1983
subcutaneous/rat 300 mg/kg (1D prior to copulation)Reproductive: Effects on fertility: Other measures of fertilityPRGLBA 1,3,1972
subcutaneous/mouse 500 mg/kg (11D pregnant)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)JTSCDR 7,177,1982
unreported route/rabbit 11250 mg/kg (16-30D pregnant)Reproductive: Effects on embryo or fetus: Fetal deathAKGIAO 43(12),10,1967
unreported route/Dog 3 gm/kg (20-34D pregnant)Reproductive: Effects on embryo or fetus: Fetal deathJZKEDZ 6,37,1980
unreported route/rat 3500 mg/kg (6-15D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Other developmental abnormalities
JACTDZ 2(4),325,1983
unreported route/woman 1200 mg/kg (20D prior to copulation)Reproductive: Maternal effects: Menstrual cycle changes or disordersCCPTAY 29,181,1984

Acute Toxicity Data and References

Route/OrganismDoseEffectReference
In Vitro/Chicken, neurons Inhibitor Concentration (50 percent kill): 8586 µmol/L/21HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 7,653,1993
In Vitro/Chicken, neurons Inhibitor Concentration (10 percent kill): 2630 µmol/L/21HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 7,653,1993
In Vitro/Chicken, neurons Inhibitor Concentration (50 percent kill): 5720 µmol/L/20HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 7,653,1993
In Vitro/Chicken, neurons Inhibitor Concentration (10 percent kill): 2460 µmol/L/20HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 7,653,1993
In Vitro/Hamster, lung fibroblast Inhibitor Concentration (50 percent kill): 1.4 mmol/L/60HIn Vitro Toxicity Studies: Cell countingTIVIEQ 7,511,1993
In Vitro/Hamster, lung fibroblast Inhibitor Concentration (10 percent kill): 0.36 mmol/L/60HIn Vitro Toxicity Studies: Cell countingTIVIEQ 7,511,1993
In Vitro/Human, blood (whole or unspecified cells) Inhibitor Concentration Low: 1 mmol/LBlood: Change in clotting factorsJOETD7 134,460,2011
In Vitro/Human, fibroblast Inhibitor Concentration Low: 30 mg/L/6HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationPYTOEY 34,202,2017
In Vitro/Human, HeLa cell Inhibitor Concentration (50 percent kill): 2.8 mmol/L/60HIn Vitro Toxicity Studies: Cell countingTIVIEQ 7,511,1993
In Vitro/Human, HeLa cell Inhibitor Concentration (10 percent kill): 0.79 mmol/L/60HIn Vitro Toxicity Studies: Cell countingTIVIEQ 7,511,1993
In Vitro/Human, liver Inhibitor Concentration (50 percent kill): 4.97 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Human, liver Inhibitor Concentration (10 percent kill): 1.8 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Human, liver Inhibitor Concentration (50 percent kill): >200 µmol/L/48HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TIVIEQ 30,429,2015
In Vitro/Human, liver Inhibitor Concentration (50 percent kill): 1024.7 mg/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 27,760,2013
In Vitro/Human, liver tumor Inhibitor Concentration (50 percent kill): 303.4 mg/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 27,760,2013
In Vitro/Human, liver tumor Inhibitor Concentration (50 percent kill): 3420 mg/LIn Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.TIVIEQ 27,1347,2013
In Vitro/Human, liver tumor Inhibitor Concentration (50 percent kill): 622 µmol/LIn Vitro Toxicity Studies: Other assays

Biochemical: Metabolism (intermediary): Effect on mitochondrial function
TIVIEQ 34,161,2016
In Vitro/Human, liver tumor Inhibitor Concentration (50 percent kill): 864 µmol/L/1HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TIVIEQ 34,161,2016
In Vitro/Human, liver tumor Inhibitor Concentration (50 percent kill): 622 µmol/L/1HBiochemical: Metabolism (intermediary): GlycolyticTIVIEQ 34,161,2016
In Vitro/Human, lung tumor Inhibitor Concentration (50 percent kill): 693.4 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.PYTOEY 21,1473,2014
In Vitro/Human, lung tumor Inhibitor Concentration Low: 100 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.PYTOEY 21,1473,2014
In Vitro/Human, lung tumor Inhibitor Concentration (50 percent kill): 2.4 mmol/L/96HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TXCYAC 278,374,2010
In Vitro/Human, neuroblastoma Inhibitor Concentration (50 percent kill): 2740 mg/LIn Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.TIVIEQ 27,1347,2013
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 596 mg/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 27,1347,2013
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 330000 mg/L/1MIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 6,367,1992
In Vitro/jkhInhibitor Concentration (50 percent kill): 2 mmol/L/96HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TXCYAC 278,374,2010
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 7.3 mmol/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 3.6 mmol/L/72HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 17.9 mmol/L/48HIn Vitro Toxicity Studies: Cell protein synthesisTIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 4.2 mmol/L/72HIn Vitro Toxicity Studies: Cell protein synthesisTIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 9.6 mmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 3.1 mmol/L/72HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 5,449,1991
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 538 mg/L/48HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 27,1347,2013
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 15 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Mouse, fibroblast Inhibitor Concentration (10 percent kill): 4.4 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): >100 µmol/L/24HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TIVIEQ 30,429,2015
In Vitro/Mouse, liver Inhibitor Concentration (50 percent kill): >6.7 mmol/L/2HBiochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases
TIVIEQ 4,783,1990
In Vitro/Mouse, macrophage Inhibitor Concentration Low: 1 µmol/L/24HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 152,151,2014
In Vitro/Mouse, macrophage Inhibitor Concentration (50 percent kill): 71.7 µmol/L/48HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 154,453,2014
In Vitro/Mouse, macrophage Inhibitor Concentration (50 percent kill): >100 µmol/L/20HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 154,453,2014
In Vitro/Mouse, macrophage Inhibitor Concentration (50 percent kill): >100 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.JOETD7 154,453,2014
In Vitro/Mouse, macrophage Inhibitor Concentration (50 percent kill): 16.4 mg/L/48HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 150,223,2013
In Vitro/paaInhibitor Concentration Low: 291 µmol/L/44HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1416,2013
In Vitro/qpaInhibitor Concentration Low: 250 µmol/L/5MIn Vitro Toxicity Studies: Other assaysFTRPAE 90,209,2013
In Vitro/Rat, intestinal Inhibitor Concentration (50 percent kill): >10 mmol/L/5HIn Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.TIVIEQ 28,1296,2014
In Vitro/Rat, intestinal Inhibitor Concentration Low: 10 mmol/L/5HIn Vitro Toxicity Studies: Other assaysTIVIEQ 28,1296,2014
In Vitro/Rat, liver Inhibitor Concentration Low: 2 mmol/L/20HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 8,55,1994
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 1160 mg/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,1347,2013
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 2.3 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Rat, liver Inhibitor Concentration (10 percent kill): 0.83 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 6,47,1992
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 1215 mg/L/20HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 5,543,1991
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 1283 mg/L/20HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 5,543,1991
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 1355 mg/L/20HIn Vitro Toxicity Studies: Cell protein synthesisTIVIEQ 5,543,1991
In Vitro/Rat, liver Inhibitor Concentration (50 percent kill): 817 mg/L/20HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 5,543,1991
In Vitro/Rat, liver tumor Inhibitor Concentration (50 percent kill): >1500 mg/L/20HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 5,543,1991
In Vitro/Rat, liver tumor Inhibitor Concentration (50 percent kill): >1500 mg/L/20HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 5,543,1991
In Vitro/Rat, liver tumor Inhibitor Concentration (50 percent kill): >1500 mg/L/20HIn Vitro Toxicity Studies: Cell protein synthesisTIVIEQ 5,543,1991
In Vitro/Rat, liver tumor Inhibitor Concentration (50 percent kill): >1500 mg/L/20HIn Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.TIVIEQ 5,543,1991
In Vitro/Rat, lung Inhibitor Concentration (50 percent kill): 1.74 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM)TIVIEQ 7,111,1993
In Vitro/Rat, lung Inhibitor Concentration (50 percent kill): 10 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 7,111,1993
In Vitro/Rat, lung Inhibitor Concentration (10 percent kill): 0.11 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM)TIVIEQ 7,111,1993
In Vitro/Rat, lung Inhibitor Concentration (75 percent kill): 9.77 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM)TIVIEQ 7,111,1993
In Vitro/Rat, lung Inhibitor Concentration (10 percent kill): 1 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 7,111,1993
In Vitro/Rat, lung Inhibitor Concentration (75 percent kill): 42.7 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 7,111,1993
intraperitoneal/mouse lowest published toxic dose: 100 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationFTRPAE 82,1190,2011
intraperitoneal/mouse lowest published toxic dose: 10 mg/kgBehavioral: AnalgesiaJOETD7 150,595,2013
intraperitoneal/mouse lowest published toxic dose: 45 mg/kgBehavioral: Analgesia

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JOETD7 144,712,2012
intraperitoneal/mouse lowest published toxic dose: 10 mg/kgBlood: Change in clotting factorsJOETD7 155,1236,2014
intraperitoneal/mouse lowest published lethal dose: 1216 mg/kgPCJOAU 34,353,2000
intraperitoneal/mouse lowest published toxic dose: 100 mg/kgGastrointestinal: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes

Biochemical: Metabolism (intermediary): Histamines (including liberation not immunochemical in origin)
EJPHAZ 460,63,2003
intraperitoneal/mouse lethal dose (50 percent kill): 167 mg/kgUSXXAM #6656449
intraperitoneal/mouse lowest published toxic dose: 10 mg/kgBehavioral: Change in psychophysiological testsPSCHDL 171,382,2004
intraperitoneal/rat lowest published toxic dose: 20 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationINJPD2 41,75,2009
intraperitoneal/rat lowest published toxic dose: 4.026 mg/kgNutritional and Gross Metabolic: Body temperature decreaseJPETAB 327,665,2008
intraperitoneal/rat lowest published toxic dose: 500 mg/kgLiver: Other changes

Biochemical: Metabolism (intermediary): Lipids including transport
EKFAE9 59,43,1996
intraperitoneal/rat lowest published toxic dose: 50 mg/kgBehavioral: AnalgesiaBJPCBM 129,343,2000
intraperitoneal/rat lethal dose (50 percent kill): 340 mg/kgNYKZAU 62,11,1966
intraperitoneal/rat lowest published toxic dose: 100 mg/kgBehavioral: Analgesia

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
FCTOD7 48,61,2010
intravenous/Dog lethal dose (50 percent kill): 681 mg/kgBehavioral: AnalgesiaAIPTAK 149,571,1964
intravenous/guinea pig lowest published toxic dose: 2 mg/kgBlood: Change in clotting factorsEJPHAZ 498,179,2004
intravenous/human lowest published toxic dose: 14.3 mg/kgBehavioral: AnalgesiaEJNSC* 26,1344,2007
intravenous/monkey lowest published toxic dose: 1 mg/kgBlood: Change in clotting factorsPHMCAA 70,100,2004
intravenous/mouse lowest published toxic dose: 250 mg/kgVascular: Measurement of regional blood flow

Gastrointestinal: Other changes

Blood: Other changes
BJPCBM 143,193,2004
intravenous/mouse lowest published toxic dose: 30 mg/kgBlood: HemorrhageTOXIA6 51,1131,2008
intravenous/mouse lowest published toxic dose: 10 mg/kgVascular: Measurement of regional blood flowEJPHAZ 455,53,2002
intravenous/mouse lowest published toxic dose: 14.1 mg/kgBehavioral: AnalgesiaNRSCDN 132,49,2005
intravenous/rat lowest published toxic dose: 30 mg/kgBlood: Change in clotting factorsTOXIA6 51,1131,2008
intravenous/rat lethal dose (50 percent kill): 495 mg/kgGWXXAW #4101325
oral/child lowest published toxic dose: 780 mg/kgCardiac: Cardiomyopathy including infarction

Lung, Thorax, or Respiration: Acute pulmonary edema

Kidney, Ureter, and Bladder: Hematuria
JEMME* 13,657,1995
oral/child lowest published toxic dose: 10 mg/kg/1D- intermittentLung, Thorax, or Respiration: Acute pulmonary edema

Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis)

Kidney, Ureter, and Bladder: Urine volume decreased or anuria
CTOXAO 18,247,1981
oral/child lowest published lethal dose: 104 mg/kgLung, Thorax, or Respiration: Acute pulmonary edema

Gastrointestinal: Nausea or vomiting

Blood: Hemorrhage
LANCAO 2,809,1952
oral/child lowest published toxic dose: 39 mg/kg/13D- intermittentLiver: Hepatitis (hepatocellular necrosis), diffuseAJDCAI 139,453,1985
oral/Dog lethal dose (50 percent kill): 700 mg/kgBehavioral: Altered sleep time (including change in righting reflex)

Lung, Thorax, or Respiration: Respiratory depression
ARZNAD 21,719,1971
oral/guinea pig lethal dose (50 percent kill): 1075 mg/kgBehavioral: Altered sleep time (including change in righting reflex)

Behavioral: Somnolence (general depressed activity)

Behavioral: Tremor
JAPMA8 47,479,1958
oral/hamster lethal dose (50 percent kill): 3500 mg/kgATSUDG 7,365,1984
oral/human lowest published toxic dose: 5.4 mg/kgVascular: Other changes

Blood: Other changes
CLPTAT 67,299,2000
oral/human lowest published toxic dose: 669 mg/kg/11DLiver: Liver function tests impairedAJHPA9 35,330,1978
oral/human lowest published toxic dose: 2880 mg/kg/8WEar: Tinnitus

Gastrointestinal: Nausea or vomiting

Gastrointestinal: Decreased motility or constipation
ARZNAD 33,631,1983
oral/human lowest published toxic dose: 480 mg/kg/7D- intermittentEar: Tinnitus

Behavioral: Somnolence (general depressed activity)

Gastrointestinal: Other changes
ARZNAD 25,281,1975
oral/human lowest published toxic dose: 1050 mg/kg/14D- intermittentVascular: Other changesCLPTAT 67,530,2000
oral/human lowest published toxic dose: 2.7 mg/kgKidney, Ureter, and Bladder: Other changes in urine composition

Immunological Including Allergic: Other immediate (humoral): uticaria, allergic rhinitis, serum sickness (multiple organ involvement)

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JACIBY 113,771,2004
oral/human lowest published toxic dose: 1.2 mg/kgBlood: Change in clotting factors

Blood: Other changes
EJPHAZ 499,315,2004
oral/human lowest published toxic dose: 2.14 mg/kgBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Blood: Other changes

Biochemical: Metabolism (intermediary): Lipids including transport
FCLPH* 17,363,2003
oral/human lowest published toxic dose: 7.143 mg/kgBiochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductasesBCLPT* 104,17,2008
oral/infant lowest published toxic dose: 120 mg/kgLung, Thorax, or Respiration: Respiratory stimulation

Kidney, Ureter, and Bladder: Hematuria

Nutritional and Gross Metabolic: Dehydration
BMJOAE 1,1081,1979
oral/mammal (species unspecified) lethal dose (50 percent kill): 1750 mg/kgIJMRAQ 81,621,1985
oral/man lowest published toxic dose: 13036 mg/kg/5Y- intermittentGastrointestinal: Other changes

Musculoskeletal: Joints

Skin: After systemic exposure: Dermatitis, other
AIMEAS 126,665,1997
oral/man lowest published toxic dose: 1625 mg/kgBehavioral: Coma

Nutritional and Gross Metabolic: Body temperature increase
CPEDAM 24,678,1985
oral/man lowest published toxic dose: 857 mg/kgBehavioral: Coma

Lung, Thorax, or Respiration: Respiratory stimulation
HUTODJ 7,161,1988
oral/mouse lethal dose (50 percent kill): 250 mg/kgUSXXAM #6656449
oral/mouse lowest published toxic dose: 300 mg/kgGastrointestinal: Ulceration or bleeding from stomachPCJOAU 36,11,2002
oral/mouse lowest published toxic dose: 23 mg/kgBehavioral: AnalgesiaJPETAB 303,340,2002
oral/mouse lowest published toxic dose: 200 mg/kgGastrointestinal: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes

Biochemical: Metabolism (intermediary): Histamines (including liberation not immunochemical in origin)
EJPHAZ 460,63,2003
oral/mouse lowest published toxic dose: 100 mg/kgBehavioral: Change in psychophysiological testsJPETAB 307,699,2003
oral/mouse lowest published lethal dose: 1216 mg/kgFRMCE8 60,203,2005
oral/mouse lowest published toxic dose: 50 mg/kgBlood: Change in clotting factorsFCTOD7 49,3018,2011
oral/mouse lowest published toxic dose: 10 mg/kgBehavioral: Analgesia

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JOETD7 152,540,2014
oral/mouse lowest published toxic dose: 10 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 149,191,2013
oral/rabbit lowest published toxic dose: 500 mg/kgGastrointestinal: Ulceration or bleeding from stomach

Gastrointestinal: Hypermotility, diarrhea

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
BDERB* 68,38,2003
oral/rabbit lethal dose (50 percent kill): 1010 mg/kgBehavioral: Change in motor activity (specific assay)GTPZAB 24(3),43,1980
oral/rat lowest published toxic dose: 150 mg/kgBehavioral: AbuseINJPD2 33,350,2001
oral/rat lowest published toxic dose: 250 mg/kgGastrointestinal: Alteration in gastric secretion

Gastrointestinal: Ulceration or bleeding from stomach
FCLPH* 16,311,2002
oral/rat lowest published toxic dose: 17 mg/kgBehavioral: AnalgesiaFATOAO 51,78,1988
oral/rat lowest published toxic dose: 50 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationPHREP* 57,802,2005
oral/rat lowest published toxic dose: 100 mg/kgBehavioral: Analgesia

Gastrointestinal: Ulceration or bleeding from stomach

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
PHREP* 57,802,2005
oral/rat lowest published toxic dose: 200 mg/kgGastrointestinal: Ulceration or bleeding from stomach

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
INJPD2 38,397,2006
oral/rat lowest published toxic dose: 300 mg/kgNutritional and Gross Metabolic: Body temperature decreaseINJPD2 38,408,2006
oral/rat lowest published toxic dose: 50 mg/kgSpinal Cord: Other degenerative changesPHMCAA 69,123,2003
oral/rat lowest published toxic dose: 50 mg/kgGastrointestinal: Alteration in gastric secretion

Gastrointestinal: Other changes

Biochemical: Metabolism (intermediary): Other
BPBLEO 31,1371,2008
oral/rat lowest published toxic dose: 120 mg/kgGastrointestinal: Necrotic changes

Blood: Hemorrhage

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JMCMAR 46,747,2003
oral/rat lethal dose (50 percent kill): 950 mg/kgCJPPA3 44,909,1966
oral/rat lowest published toxic dose: 100 mg/kgBehavioral: Analgesia

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JOETD7 158,271,2014
oral/rat lowest published toxic dose: 150 mg/kgGastrointestinal: Ulceration or bleeding from stomachFITOT* 82,666,2011
oral/rat lowest published toxic dose: 500 mg/kgGastrointestinal: Ulceration or bleeding from stomach

Gastrointestinal: Other changes
PYTOEY 18,91,2011
oral/woman lowest published toxic dose: 194.4 mg/kgEar: Tinnitus

Gastrointestinal: Nausea or vomiting
APHRER 38,1186,2004
oral/woman lowest published toxic dose: 194.4 mg/kgEar: Tinnitus

Gastrointestinal: Other changes

Blood: Other changes
APHRER 38,1186,2004
oral/woman lowest published toxic dose: 13 mg/kgVascular: Other changes

Immunological Including Allergic: Other immediate (humoral): uticaria, allergic rhinitis, serum sickness (multiple organ involvement)
APHRER 39,944,2005
oral/woman lowest published toxic dose: 200 mg/kgKidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis)

Kidney, Ureter, and Bladder: Proteinuria

Nutritional and Gross Metabolic: Changes in: Metabolic acidosis
AJKDDP 50,463,2007
oral/woman lowest published toxic dose: 525 mg/kg/5D- intermittentLiver: Hepatitis (hepatocellular necrosis), diffuseAIMEAS 80,74,1974
oral/woman lowest published toxic dose: 480 mg/kg/5D- intermittentKidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis)

Biochemical: Metabolism (intermediary): Other
NEJMAG 296,418,1977
oral/woman lowest published toxic dose: 800 mg/kgKidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis)

Musculoskeletal: Other changes
AJEMEN 7,409,1989
rectal/rat lethal dose (50 percent kill): 790 mg/kg34ZIAG -,67,1969
rectal/woman lowest published toxic dose: 4550 mg/kgBrain and Coverings: Encephalitis

Behavioral: Coma

Cardiac: Arrythmias (indlucing changes in conduction)
APHRER 28,467,1994
skin/mouse lowest published toxic dose: 50 mg/kgImmunological Including Allergic: Decrease in cellular immune responseFATOAO 47,84,1984
skin/rat lowest published toxic dose: 50 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationFATOAO 47,84,1984
subcutaneous/mouse lethal dose (50 percent kill): 1020 mg/kgCPBTAL 28,1237,1980
subcutaneous/mouse lowest published toxic dose: 10 mg/kgBehavioral: AnalgesiaFCLPH* 20,365,2006
subcutaneous/rat lowest published toxic dose: 5 mg/kgBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationPYTOEY 10,375,2003
Tank with water/Zebrafish lowest published toxic concentration: 1000 µmol/L/48HReproductive: Specific developmental abnormalities: Gastrointestinal systemTXAPA9 272,272,2013
unreported route/man lowest published lethal dose: 294 mg/kg85DCAI 2,73,1970
unreported route/mouse lethal dose (50 percent kill): 1350 mg/kgUSXXAM #5240918
unreported route/mouse lowest published toxic dose: 100 mg/kgBehavioral: AnalgesiaJOETD7 144,726,2012

Other Multiple Dose Data and References

Route/OrganismDoseEffectReference
inhalation/rat lowest published toxic concentration: 25 mg/m3/4H/17W- intermittentBrain and Coverings: Recordings from specific areas of CNS

Blood: Change in clotting factors

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)
GTPZAB 24(3),43,1980
intraperitoneal/mouse lowest published toxic dose: 700 mg/kg/7D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationFTRPAE 81,855,2010
intraperitoneal/mouse lowest published toxic dose: 14.0 mg/kg/7D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 155,1300,2014
intraperitoneal/rat lowest published toxic dose: 8750 mg/kg/21D- intermittentKidney, Ureter, and Bladder: Changes in both tubules and glomeruliJDGRAX 19,327,1990
intraperitoneal/rat lowest published toxic dose: 60 mg/kg/3D- intermittentGastrointestinal: Ulceration or bleeding from stomachCPBTAL 55,76,2007
oral/Dog lowest published toxic dose: 1200 mg/kg/2D- intermittentBlood: Change in clotting factorsFATOBP 159,19,1986
oral/Dog lowest published toxic dose: 12000 mg/kg/10D- intermittentBlood: Change in clotting factorsFATOAO 49,49,1986
oral/human lowest published toxic dose: 85.8 mg/kg/30D- intermittentGastrointestinal: Ulceration or bleeding from duodeumNEJMAG 343,834,2000
oral/human lowest published toxic dose: 10 mg/kg/7D- intermittentGastrointestinal: Ulceration or bleeding from stomachEJCPAS -,S85,2002
oral/human lowest published toxic dose: 261.507 mg/kg/183D- intermittentBlood: Change in clotting factorsNSAPCC 372(Suppl 1),147,2006
oral/human lowest published toxic dose: 6.4 mg/kg/3D- intermittentBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Blood: Other changes

Biochemical: Metabolism (intermediary): Lipids including transport
FCLPH* 17,363,2003
oral/human lowest published toxic dose: 3.5 mg/kg/5D- intermittentGastrointestinal: Hypermotility, diarrhea

Gastrointestinal: Nausea or vomiting
PYTOEY 18,437,2011
oral/human lowest published toxic dose: 29032 mg/kg/20Y- intermittentGastrointestinal: Other changesBJCAAI 95,1277,2006
oral/human lowest published toxic dose: 834.29 mg/kg/1Y- intermittentGastrointestinal: Other changes

Tumorigenic: Active as anti-cancer agent
FCLPH* 23(Suppl 1),111,2009
oral/man lowest published toxic dose: 30.1 mg/kg/7D- intermittentBehavioral: Change in psychophysiological testsPSCHDL 205,151,2009
oral/man lowest published toxic dose: 0.087 gm/kg/3D- intermittentGastrointestinal: Ulceration or bleeding from stomach

Gastrointestinal: Other changes
JPHPH* 59,67,2008
oral/man lowest published toxic dose: 8395 mg/kg/5Y- intermittentReproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glandsJNCIEQ 97,975,2005
oral/man lowest published toxic dose: 2555 mg/kg/5Y- intermittentBlood: EosinophiliaAPHRER 38,2172,2004
oral/mouse lowest published toxic dose: 12600 mg/kg/7D- intermittentBlood: Normocytic anemia

Blood: Changes in bone marrow not included in above

Blood: Changes in leukocyte (WBC) count
INJPD2 36,226,2004
oral/mouse lowest published toxic dose: 22500 mg/kg/25W- intermittentBlood: Normocytic anemia

Blood: Changes in bone marrow not included in above

Blood: Changes in leukocyte (WBC) count
INJPD2 36,226,2004
oral/mouse lowest published toxic dose: 900 mg/kg/3D- intermittentBehavioral: Analgesia

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
BPBLEO 31,1761,2008
oral/mouse lowest published toxic dose: 36 mg/kg/3D- continuousLiver: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
JCINAO 119,305,2009
oral/mouse lowest published toxic dose: 1000 mg/kg/5D- intermittentBehavioral: AnalgesiaFTRPAE 81,178,2010
oral/mouse lowest published toxic dose: 1400 mg/kg/7D- intermittentJOETD7 150,501,2013
oral/mouse lowest published toxic dose: 70 mg/kg/14D- intermittentJOETD7 154,163,2014
oral/mouse lowest published toxic dose: 1000 mg/kg/10D- intermittentBlood: Change in clotting factorsJOETD7 151,151,2014
oral/mouse lowest published toxic dose: 0.3 gm/kg/3D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 152,444,2014
oral/mouse lowest published toxic dose: 371 mg/kg/7D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 187,259,2016
oral/mouse lowest published toxic dose: 500 mg/kg/5D- intermittentGastrointestinal: Ulceration or bleeding from stomach

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
PYTOEY 23,1227,2016
oral/rabbit lowest published toxic dose: 3250 mg/kg/13D- intermittentBehavioral: Somnolence (general depressed activity)

Gastrointestinal: Hypermotility, diarrhea
BDERB* 68,38,2003
oral/rabbit lowest published toxic dose: 2500 mg/kg/10D- intermittentGastrointestinal: Other changes

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
BDERB* 68,38,2003
oral/rabbit lowest published toxic dose: 1750 mg/kg/7D- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gainBDERB* 68,38,2003
oral/rabbit lowest published toxic dose: 1500 mg/kg/6D- intermittentBehavioral: Food intake (animal)BDERB* 68,38,2003
oral/rat lowest published toxic dose: 875 mg/kg/7D- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gainBDERB* 68,27,2003
oral/rat lowest published toxic dose: 400 mg/kg/2D- intermittentBlood: HemorrhageEJPHAZ 587,209,2008
oral/rat lowest published toxic dose: 7056 mg/kg/42W- continuousTumorigenic: Active as anti-cancer agentCNREA8 66,4542,2006
oral/rat lowest published toxic dose: 150 mg/kg/5D- intermittentVascular: Other changes

Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation
ACPSI* 25,1633,2004
oral/rat lowest published toxic dose: 2100 mg/kg/21D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationEJPHAZ 551,131,2006
oral/rat lowest published toxic dose: 1440 mg/kg/4D- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
TXCYAC 232,257,2007
oral/rat lowest published toxic dose: 360 mg/kg/4D- intermittentReproductive: Other effects on femaleTXCYAC 232,257,2007
oral/rat lowest published toxic dose: 1400 mg/kg/2W- intermittentCardiac: Other changes

Kidney, Ureter, and Bladder: Changes primarily in glomeruli

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
HETOEA 22,143,2003
oral/rat lowest published toxic dose: 1500 mg/kg/2W- intermittentLiver: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXCYAC 188,161,2003
oral/rat lowest published toxic dose: 180 mg/kg/10D- intermittentBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)EJPHAZ 477,59,2003
oral/rat lowest published toxic dose: 32.4 mg/kg/3D- intermittentBlood: Change in clotting factorsEKFAE9 62,38,1999
oral/rat lowest published toxic dose: 560 mg/kg/4W- continuousSkin and Appendages: Tumors

Tumorigenic: Protects against induction of experimental tumors

Tumorigenic: Active as anti-cancer agent
CALEDQ 143,195,1999
oral/rat lowest published toxic dose: 2500 mg/kg/10D- intermittentEndocrine: Hypoglycemia

Blood: Other changes
FATOBP 159,75,1986
oral/rat lowest published toxic dose: 5000 mg/kg/10D- intermittentEndocrine: Other changes

Blood: Other changes
FATOBP 159,75,1986
oral/rat lowest published toxic dose: 9500 mg/kg/3W- intermittentRelated to Chronic Data: Death in the "MULTIPLE DOSE" data type fieldJPETAB 89,205,1947
oral/rat lowest published toxic dose: 200 mg/kg/4D- intermittentGastrointestinal: Ulceration or bleeding from stomachTXAPA9 52,454,1980
oral/rat lowest published toxic dose: 8127 mg/kg/43W- continuousKidney, Ureter, and Bladder: Other changes in urine compositionAPTOA6 26,105,1968
oral/rat lowest published toxic dose: 1320 mg/kg/11D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 194,228,2016
oral/rat lowest published toxic dose: 1600 mg/kg/16D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 152,522,2014
oral/rat lowest published toxic dose: 75 mg/kg/15D- intermittentBlood: Change in clotting factorsJOETD7 159,184,2015
oral/rat lowest published toxic dose: 145.74 mg/kg/14D- intermittentGastrointestinal: Alteration in gastric secretion

Gastrointestinal: Gastritis

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases
PYTOEY 23,662,2016
oral/rat lowest published toxic dose: 600 mg/kg/6D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 187,17,2016
oral/rat lowest published toxic dose: 1400 mg/kg/7D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationJOETD7 151,343,2014
oral/rat lowest published toxic dose: 70 mg/kg/14D- intermittentJOETD7 154,163,2014
oral/rat lowest published toxic dose: 600 mg/kg/3D- intermittentGastrointestinal: Ulceration or bleeding from stomachJOETD7 134,195,2011
oral/rat lowest published toxic dose: 51.5 mg/kg/5D- intermittentBlood: Change in clotting factorsJOETD7 143,648,2012
oral/rat lowest published toxic dose: 700 mg/kg/4D- intermittentBlood: Change in clotting factors

Blood: Other changes
FCTOD7 47,1797,2009
oral/rat lowest published toxic dose: 420 mg/kg/6W- continuousCardiac: Changes in heart weight

Kidney, Ureter, and Bladder: Changes in blood vessels or in circulation of kidney

Vascular: Other changes
CEXPB9 36,162,2009
oral/rat lowest published toxic dose: 400 mg/kg/5D- intermittentGastrointestinal: Other changes

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases
FCTOD7 48,2785,2010
oral/rat lowest published toxic dose: 12000 mg/kg/120D- continuousBlood: Other changes

Biochemical: Metabolism (intermediary): Lipids including transport

Biochemical: Metabolism (intermediary): Plasma proteins not involving coagulation
JPETAB 324,850,2008
oral/rat lowest published toxic dose: 6000 mg/kg/60D- continuousBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other esterases
JPETAB 324,850,2008
oral/rat lowest published toxic dose: 10 mg/kg/2D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationPYTOEY 10,375,2003
oral/rat lowest published toxic dose: 1350 mg/kg/3D- intermittentBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)HETOEA 28,231,2009
oral/rat lowest published toxic dose: 450 mg/kg/15D- intermittentGastrointestinal: Ulceration or bleeding from stomachJPETAB 311,1264,2004
oral/woman lowest published toxic dose: 455 mg/kg/7D- intermittentBehavioral: Somnolence (general depressed activity)

Behavioral: Tremor

Nutritional and Gross Metabolic: Body temperature increase
JTCTDW 45,526,2007
oral/woman lowest published toxic dose: 0.36 mg/kg/24W- intermittentLung, Thorax, or Respiration: TumorsBJCAAI 87,49,2002
oral/woman lowest published toxic dose: 261 mg/kg/5Y- intermittentSkin and Appendages: Other: Breast

Tumorigenic: Active as anti-cancer agent
CNREA8 63,6096,2003
oral/woman lowest published toxic dose: 300 mg/kg/3D- intermittentBehavioral: Coma

Nutritional and Gross Metabolic: Changes in: Metabolic acidosis

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
NRTXDN 28,33,2007
oral/woman lowest published toxic dose: 13559 mg/kg/20Y- intermittentGastrointestinal: Changes in structure or function of exocrine pancreas

Gastrointestinal: Tumors
JNCIEQ 96,22,2004
skin/mouse lowest published toxic dose: 500 mg/kg/10D- intermittentBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationFATOAO 47,84,1984
subcutaneous/mouse lowest published toxic dose: 2520 mg/kg/3W- continuousEndocrine: Hypoglycemia

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)
SCIEAS 293,1673,2001
subcutaneous/rat lowest published toxic dose: 840 mg/kg/1W- continuousBlood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Biochemical: Metabolism (intermediary): Lipids including transport
SCIEAS 293,1673,2001
subcutaneous/rat lowest published toxic dose: 2520 mg/kg/3W- continuousEndocrine: Hypoglycemia

Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)

Biochemical: Metabolism (intermediary): Lipids including transport
SCIEAS 293,1673,2001
unreported route/human lowest published toxic dose: 8.4 mg/kg/6D- intermittentBlood: Other changes

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases
JPETAB 322,453,2007

Reviews

OrganizationStandardReference
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-time-weighted average 5 mg/m3DTLVS* TLV/BEI,2013
TOXICOLOGY REVIEWBCSTB5 2,695,1974
TOXICOLOGY REVIEWDICPBB 9,350,1975
TOXICOLOGY REVIEWDICPBB 8,690,1974
TOXICOLOGY REVIEWPLMJAP 6,160,1975
TOXICOLOGY REVIEWJPHAA3 NS16,147,1976
TOXICOLOGY REVIEWAUHPAI 3(3),100,1973
TOXICOLOGY REVIEWJRPMAP 12,27,1974
TOXICOLOGY REVIEWCLCHAU 19,361,1973
TOXICOLOGY REVIEWAJMEAZ 38,409,1965
TOXICOLOGY REVIEWATXKA8 28,135,1971
TOXICOLOGY REVIEWAIMDAP 141,358,1981
TOXICOLOGY REVIEWJJIND8 94,252,2002
TOXICOLOGY REVIEWREPTED 17,255,2003
TOXICOLOGY REVIEWMUREAV 488,151,2001
TOXICOLOGY REVIEWTOLED5 144,383,2003
TOXICOLOGY REVIEWEMMUEG 43,143,2004
TOXICOLOGY REVIEWTPHSDY 24,245,2003
TOXICOLOGY REVIEWTPHSDY 24,154,2003
TOXICOLOGY REVIEWTPHSDY 24,323,2003
TOXICOLOGY REVIEWTPHSDY 24,331,2003
TOXICOLOGY REVIEWTPHSDY 24,335,2003
TOXICOLOGY REVIEWAPHRER 37,1675,2003
TOXICOLOGY REVIEWAPHRER 39,51,2005
TOXICOLOGY REVIEWAPHRER 39,944,2005
TOXICOLOGY REVIEWJPETAB 314,1,2005
TOXICOLOGY REVIEWAJMEAZ 119,624,2006
TOXICOLOGY REVIEWAJMEAZ 119,552,2006
TOXICOLOGY REVIEWAINCM* 7,63,2006
TOXICOLOGY REVIEWBPCEM* 17,237,2003
TOXICOLOGY REVIEWENTOX* -,36,2005
TOXICOLOGY REVIEWEJIME* 17,529,2006
TOXICOLOGY REVIEWDIMON* 40,258,1994
TOXICOLOGY REVIEWDIMON* 39,678,1993
TOXICOLOGY REVIEWJEMME* 32,63,2007
TOXICOLOGY REVIEWENTOX* -,742,2005
TOXICOLOGY REVIEWBJPCBM 146,477,2005
TOXICOLOGY REVIEWBJPCBM 147,S241,2006
TOXICOLOGY REVIEWTOPADD 32(Suppl. 2),71,2004
TOXICOLOGY REVIEWFCLPH* 17,393,2003
TOXICOLOGY REVIEWAJEMEN 22,404,2004
TOXICOLOGY REVIEWPHREP* 59,247,2007
TOXICOLOGY REVIEWMJAUAJ 185,501,2006
TOXICOLOGY REVIEWHUTOX* -,411,1996
TOXICOLOGY REVIEWJPHPH* 59,117,2008
TOXICOLOGY REVIEWJPHPH* 59(Suppl 2),89,2008
TOXICOLOGY REVIEWJPHPH* 59(Suppl 2),117,2008
TOXICOLOGY REVIEWBPRCR* 16,105,2002
TOXICOLOGY REVIEWAJMEAZ 121,464,2008
TOXICOLOGY REVIEWBLREV* 3,71,1989
TOXICOLOGY REVIEWCLLID* 11,563,2007
TOXICOLOGY REVIEWCOCPH* -,701,2008
TOXICOLOGY REVIEWCLLID* 13,277,2009
TOXICOLOGY REVIEWCCACL* 22,357,2006
TOXICOLOGY REVIEWDERCL* 25,215,2007
TOXICOLOGY REVIEWDERCL* 27,289,2009
TOXICOLOGY REVIEWMUTAEX 23,271,2008
TOXICOLOGY REVIEWNCLNA* 16,107,1998
TOXICOLOGY REVIEWMEDIAV 37,263,2009
TOXICOLOGY REVIEWNBREV* 5,1,1981
TOXICOLOGY REVIEWNBREV* 11,35,1987
TOXICOLOGY REVIEWFCLPH* 22(Suppl 1),30,2008
TOXICOLOGY REVIEWFCLPH* 23(Suppl 1),15,2009
TOXICOLOGY REVIEWFCLPH* 22,335,2008
TOXICOLOGY REVIEWFCLPH* 23,105,2009
TOXICOLOGY REVIEWREPTED 30,495,2010
TOXICOLOGY REVIEWMUREAV 750,132,2012
TOXICOLOGY REVIEWMUREAV 750,1,2012
TOXICOLOGY REVIEWMUREAV 760,1,2014
TOXICOLOGY REVIEWJOETD7 181,66,2016
TOXICOLOGY REVIEWJOETD7 181,118,2016
TOXICOLOGY REVIEWRTOPDW 56,237,2010
TOXICOLOGY REVIEWRTOPDW 58,395,2010
TOXICOLOGY REVIEWSFDRA* 38,365,2016
TOXICOLOGY REVIEWVETODR ,197,2018
TOXICOLOGY REVIEWVETOX* ,357,2018

Standards and Regulations

OrganizationStandardReference
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDESActive registrationRBREV* -,351,1998
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIAtime-weighted average 5 mg/m3, JUL2008
Occupational Exposure Limit-AUSTRIAMAK-TMW 5 mg/m3;KZW 10 mg/m3, inhal, 2007
Occupational Exposure Limit-BELGIUMtime-weighted average 5 mg/m3, MAR2002
Occupational Exposure Limit-DENMARKtime-weighted average 5 mg/m3, MAY2011
Occupational Exposure Limit-ICELANDtime-weighted average 5 mg/m3, NOV2011
Occupational Exposure Limit-KOREAtime-weighted average 5 mg/m3, 2006
Occupational Exposure Limit-NEW ZEALANDtime-weighted average 5 mg/m3, JAN2002
Occupational Exposure Limit-NORWAYtime-weighted average 5 gm/m3, JAN1999
Occupational Exposure Limit-PERUtime-weighted average 5 mg/m3, JUL2005
Occupational Exposure Limit-RUSSIAshort term exposure limit 0.5 mg/m3, JUN2003
Occupational Exposure Limit-SWITZERLANDMAK-week 5 mg/m3, inhal, JAN2011
Occupational Exposure Limit-THE NETHERLANDSMAC-TGG 5 mg/m3, 2003
Occupational Exposure Limit-UNITED KINGDOMtime-weighted average 5 mg/m3, OCT2007

NIOSH Documentation and Surveillance

OrganizationStandardReference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ACETYLSALICYLIC ACID-air10H time-weighted average 5 mg/m3NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983Hazard Code X1189; Number of Industries 1; Total Number of Facilities 27; Number of Occupations 1; Total Number of Employees Exposed 191; Total Number of Female Employees Exposed 82
National Occupational Exposure Survey 1983Hazard Code 84517; Number of Industries 9; Total Number of Facilities 491; Number of Occupations 22; Total Number of Employees Exposed 10776; Total Number of Female Employees Exposed 6083
National Occupational Hazard Survey 1974Hazard Code 84517; Number of Industries 12; Total Number of Facilities 1746; Number of Occupations 16; Total Number of Employees Exposed 10452

Status in Federal Agencies

OrganizationReference
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
Page last reviewed: November 16, 2018